[144] ABBVIE INC. SEC Filing
AbbVie (ABBV) filed a Form 144 reporting proposed sales of common stock through Northern Trust Securities on the NYSE. The notice lists three proposed transactions: 61,500 shares (aggregate market value $12,043,268.25, approx. sale date 08/01/2025), 35,120 shares ($6,828,296.22, 08/04/2025) and 91,600 shares ($19,208,000, 08/04/2025). The filing shows a reported number of outstanding shares of 1,766,558,253.
The document discloses the acquisition history for the securities to be sold, showing they were received as restricted stock in grants dated between 02/28/2017 and 02/26/2021 with specific grant amounts listed. The filer indicates no securities sold in the past three months and includes the standard Rule 144 attestation about lack of undisclosed material adverse information.
AbbVie (ABBV) ha presentato un Form 144 segnalando vendite proposte di azioni ordinarie tramite Northern Trust Securities sul NYSE. L'avviso elenca tre transazioni proposte: 61,500 azioni (valore di mercato complessivo $12,043,268.25, data indicativa di vendita 08/01/2025), 35,120 azioni ($6,828,296.22, 08/04/2025) e 91,600 azioni ($19,208,000, 08/04/2025). Il deposito riporta un numero di azioni in circolazione pari a 1,766,558,253.
Il documento rende note le modalit脿 di acquisizione dei titoli da vendere, indicando che sono stati ricevuti come azioni soggette a restrizioni in grant datati tra il 02/28/2017 e il 02/26/2021, con gli importi specifici elencati. Il dichiarante segnala di non aver venduto titoli negli ultimi tre mesi e include la consueta attestazione della Rule 144 sull'assenza di informazioni materiali sfavorevoli non divulgate.
AbbVie (ABBV) present贸 un Formulario 144 notificando ventas propuestas de acciones ordinarias a trav茅s de Northern Trust Securities en la NYSE. El aviso enumera tres operaciones propuestas: 61,500 acciones (valor de mercado agregado $12,043,268.25, fecha aproximada de venta 08/01/2025), 35,120 acciones ($6,828,296.22, 08/04/2025) y 91,600 acciones ($19,208,000, 08/04/2025). La presentaci贸n muestra un n煤mero reportado de acciones en circulaci贸n de 1,766,558,253.
El documento divulga el historial de adquisici贸n de los valores a vender, mostrando que fueron recibidos como acciones sujetas a restricciones en concesiones fechadas entre el 02/28/2017 y el 02/26/2021, con los montos espec铆ficos listados. El declarante indica que no vendi贸 valores en los 煤ltimos tres meses e incluye la atestaci贸n est谩ndar de la Regla 144 sobre la ausencia de informaci贸n material adversa no divulgada.
AbbVie (ABBV)電� NYSE鞐愳劀 Northern Trust Securities毳� 韱淀暣 氤错喌欤� 毵る弰毳� 鞝滌晥頃橂姅 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 瓿店碃鞐愲姅 靹� 瓯挫潣 鞓堨爼 瓯半灅臧� 旮办灛霅橃柎 鞛堨姷雼堧嫟: 61,500欤�(齑� 鞁滉皜 $12,043,268.25, 鞓堨儊 毵り皝鞚� 08/01/2025), 35,120欤�($6,828,296.22, 08/04/2025), 攴鸽Μ瓿� 91,600欤�($19,208,000, 08/04/2025). 鞝滌稖靹滊鞐愲姅 氚滍枆欤检嫕 齑濎垬 1,766,558,253欤缄皜 氤搓碃霅橃柎 鞛堨姷雼堧嫟.
氍胳劀電� 毵る弰 雽�靸� 歃濌秾鞚� 旆摑 鞚措牓鞚� 瓿店皽頃橂┌, 頃措嫻 欤检嫕霌れ澊 02/28/2017瓿� 02/26/2021 靷澊鞐� 攵�鞐悳 鞝滍暅欤检嫕(Restricted Stock)鞙茧 靾橂牴霅橃棃鞚岇潉 甑泊鞝侅澑 攵�鞐� 旮堨暋瓿� 頃粯 氤挫棳欷嶋媹雼�. 鞝滌稖鞚胳潃 斓滉芳 3臧滌洈 雮挫棎 歃濌秾鞚� 毵る弰頃� 氚� 鞐嗢潓鞚� 氇呾嫓頄堨溂氅�, 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗠嫟電� Rule 144鞚� 響滌 歆勳垹鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
AbbVie (ABBV) a d茅pos茅 un formulaire 144 signalant des ventes envisag茅es d'actions ordinaires via Northern Trust Securities sur le NYSE. L'avis mentionne trois op茅rations propos茅es : 61,500 actions (valeur de march茅 totale $12,043,268.25, date approximative de vente 08/01/2025), 35,120 actions ($6,828,296.22, 08/04/2025) et 91,600 actions ($19,208,000, 08/04/2025). Le d茅p么t indique un nombre d'actions en circulation d茅clar茅 de 1,766,558,253.
Le document r茅v猫le l'historique d'acquisition des titres 脿 vendre, montrant qu'ils ont 茅t茅 re莽us sous forme d'actions soumises 脿 des restrictions dans des attributions dat茅es entre le 02/28/2017 et le 02/26/2021, avec les montants sp茅cifiques list茅s. Le d茅clarant indique n'avoir vendu aucun titre au cours des trois derniers mois et inclut l'attestation standard de la Rule 144 concernant l'absence d'informations d茅favorables importantes non divulgu茅es.
AbbVie (ABBV) hat ein Formular 144 eingereicht, in dem vorgeschlagene Verk盲ufe von Stammaktien 眉ber Northern Trust Securities an der NYSE gemeldet werden. Die Mitteilung listet drei geplante Transaktionen auf: 61,500 Aktien (Gesamtmarktwert $12,043,268.25, voraussichtliches Verkaufsdatum 08/01/2025), 35,120 Aktien ($6,828,296.22, 08/04/2025) und 91,600 Aktien ($19,208,000, 08/04/2025). Die Einreichung weist eine gemeldete Anzahl ausstehender Aktien von 1,766,558,253 aus.
Das Dokument legt die Erwerbshistorie der zu verkaufenden Wertpapiere offen und zeigt, dass sie als gesperrte Aktien (Restricted Stock) in Grants mit Daten zwischen 02/28/2017 und 02/26/2021 erhalten wurden, wobei die jeweiligen Grant-Betr盲ge aufgef眉hrt sind. Der Einreicher gibt an, in den letzten drei Monaten keine Wertpapiere ver盲u脽ert zu haben, und f眉gt die 眉bliche Rule鈥�144鈥慐rkl盲rung hinzu, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen.
- Filing provides full transaction detail: share counts, aggregate market values, broker (Northern Trust), exchange (NYSE) and approximate sale dates are disclosed
- Acquisition provenance disclosed: all securities to be sold are listed as acquired as restricted stock with grant dates between 2017 and 2021
- No recent sales reported in the past three months, as indicated by the filing
- Insider liquidity planned: proposed sales include tranches with aggregate market values listed up to $19,208,000
- Material amount disclosed: the three proposed tranches list aggregate values of $12,043,268.25, $6,828,296.22, and $19,208,000, which together represent sizeable individual transactions
Insights
TL;DR: Routine Rule 144 notice disclosing planned insider sales totaling multiple tranches in August 2025; transparency is provided on grant origin.
The filing lists three proposed sales executed via Northern Trust on the NYSE: 61,500; 35,120; and 91,600 common shares, each with stated aggregate market values. The securities to be sold were acquired as restricted stock across 2017鈥�2021, with specific grant sizes reported. No sales were reported in the prior three months. From a market-impact perspective, the document is a compliance disclosure rather than new operational information; it quantifies planned insider liquidity while confirming the shares originated from compensation grants.
TL;DR: The Form 144 provides required transparency about an insider's planned share disposals and the restricted-stock origin of those holdings.
The form complies with Rule 144 disclosure by naming the broker (Northern Trust), listing exact share counts, aggregate market values, and approximate sale dates in August 2025. It also itemizes the acquisition dates and nature of the holdings (restricted stock), which helps assess vesting and compensation-related sales. The attestation that no undisclosed material adverse information is known is present, consistent with filing norms. Governance implications are informational rather than corrective.
AbbVie (ABBV) ha presentato un Form 144 segnalando vendite proposte di azioni ordinarie tramite Northern Trust Securities sul NYSE. L'avviso elenca tre transazioni proposte: 61,500 azioni (valore di mercato complessivo $12,043,268.25, data indicativa di vendita 08/01/2025), 35,120 azioni ($6,828,296.22, 08/04/2025) e 91,600 azioni ($19,208,000, 08/04/2025). Il deposito riporta un numero di azioni in circolazione pari a 1,766,558,253.
Il documento rende note le modalit脿 di acquisizione dei titoli da vendere, indicando che sono stati ricevuti come azioni soggette a restrizioni in grant datati tra il 02/28/2017 e il 02/26/2021, con gli importi specifici elencati. Il dichiarante segnala di non aver venduto titoli negli ultimi tre mesi e include la consueta attestazione della Rule 144 sull'assenza di informazioni materiali sfavorevoli non divulgate.
AbbVie (ABBV) present贸 un Formulario 144 notificando ventas propuestas de acciones ordinarias a trav茅s de Northern Trust Securities en la NYSE. El aviso enumera tres operaciones propuestas: 61,500 acciones (valor de mercado agregado $12,043,268.25, fecha aproximada de venta 08/01/2025), 35,120 acciones ($6,828,296.22, 08/04/2025) y 91,600 acciones ($19,208,000, 08/04/2025). La presentaci贸n muestra un n煤mero reportado de acciones en circulaci贸n de 1,766,558,253.
El documento divulga el historial de adquisici贸n de los valores a vender, mostrando que fueron recibidos como acciones sujetas a restricciones en concesiones fechadas entre el 02/28/2017 y el 02/26/2021, con los montos espec铆ficos listados. El declarante indica que no vendi贸 valores en los 煤ltimos tres meses e incluye la atestaci贸n est谩ndar de la Regla 144 sobre la ausencia de informaci贸n material adversa no divulgada.
AbbVie (ABBV)電� NYSE鞐愳劀 Northern Trust Securities毳� 韱淀暣 氤错喌欤� 毵る弰毳� 鞝滌晥頃橂姅 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 瓿店碃鞐愲姅 靹� 瓯挫潣 鞓堨爼 瓯半灅臧� 旮办灛霅橃柎 鞛堨姷雼堧嫟: 61,500欤�(齑� 鞁滉皜 $12,043,268.25, 鞓堨儊 毵り皝鞚� 08/01/2025), 35,120欤�($6,828,296.22, 08/04/2025), 攴鸽Μ瓿� 91,600欤�($19,208,000, 08/04/2025). 鞝滌稖靹滊鞐愲姅 氚滍枆欤检嫕 齑濎垬 1,766,558,253欤缄皜 氤搓碃霅橃柎 鞛堨姷雼堧嫟.
氍胳劀電� 毵る弰 雽�靸� 歃濌秾鞚� 旆摑 鞚措牓鞚� 瓿店皽頃橂┌, 頃措嫻 欤检嫕霌れ澊 02/28/2017瓿� 02/26/2021 靷澊鞐� 攵�鞐悳 鞝滍暅欤检嫕(Restricted Stock)鞙茧 靾橂牴霅橃棃鞚岇潉 甑泊鞝侅澑 攵�鞐� 旮堨暋瓿� 頃粯 氤挫棳欷嶋媹雼�. 鞝滌稖鞚胳潃 斓滉芳 3臧滌洈 雮挫棎 歃濌秾鞚� 毵る弰頃� 氚� 鞐嗢潓鞚� 氇呾嫓頄堨溂氅�, 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗠嫟電� Rule 144鞚� 響滌 歆勳垹鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
AbbVie (ABBV) a d茅pos茅 un formulaire 144 signalant des ventes envisag茅es d'actions ordinaires via Northern Trust Securities sur le NYSE. L'avis mentionne trois op茅rations propos茅es : 61,500 actions (valeur de march茅 totale $12,043,268.25, date approximative de vente 08/01/2025), 35,120 actions ($6,828,296.22, 08/04/2025) et 91,600 actions ($19,208,000, 08/04/2025). Le d茅p么t indique un nombre d'actions en circulation d茅clar茅 de 1,766,558,253.
Le document r茅v猫le l'historique d'acquisition des titres 脿 vendre, montrant qu'ils ont 茅t茅 re莽us sous forme d'actions soumises 脿 des restrictions dans des attributions dat茅es entre le 02/28/2017 et le 02/26/2021, avec les montants sp茅cifiques list茅s. Le d茅clarant indique n'avoir vendu aucun titre au cours des trois derniers mois et inclut l'attestation standard de la Rule 144 concernant l'absence d'informations d茅favorables importantes non divulgu茅es.
AbbVie (ABBV) hat ein Formular 144 eingereicht, in dem vorgeschlagene Verk盲ufe von Stammaktien 眉ber Northern Trust Securities an der NYSE gemeldet werden. Die Mitteilung listet drei geplante Transaktionen auf: 61,500 Aktien (Gesamtmarktwert $12,043,268.25, voraussichtliches Verkaufsdatum 08/01/2025), 35,120 Aktien ($6,828,296.22, 08/04/2025) und 91,600 Aktien ($19,208,000, 08/04/2025). Die Einreichung weist eine gemeldete Anzahl ausstehender Aktien von 1,766,558,253 aus.
Das Dokument legt die Erwerbshistorie der zu verkaufenden Wertpapiere offen und zeigt, dass sie als gesperrte Aktien (Restricted Stock) in Grants mit Daten zwischen 02/28/2017 und 02/26/2021 erhalten wurden, wobei die jeweiligen Grant-Betr盲ge aufgef眉hrt sind. Der Einreicher gibt an, in den letzten drei Monaten keine Wertpapiere ver盲u脽ert zu haben, und f眉gt die 眉bliche Rule鈥�144鈥慐rkl盲rung hinzu, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen.
FAQ
What did ABBV file in this Form 144?
How many ABBV shares are proposed for sale and what are the aggregate values?
Where will the ABBV shares be sold?
What is the origin of the shares being sold?
Has the filer sold ABBV securities in the past three months?
